ResMed price target raised to $265 from $260 at Stifel

Stifel raised the firm’s price target on ResMed (RMD) to $265 from $260 and keeps a Hold rating on the shares following fiscal Q2 results. While the firm calls it a “good quarter,” it also highlight what it calls “a couple blemishes.”